Enhertu (Trastuzumab deruxtecan)
trastuzumab deruxtecan 100 mg injection, 1 vial · INJECTION · PBS code 14578G
AUTHORITY_REQUIREDWhat it costs
AU$2493.06 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-09-01.
- • Repeats: 8.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Unresectable and/or metastatic HER2-low breast cancer
Patient must have evidence of human epidermal growth factor receptor 2 (HER2)-low disease; AND
Patient must have received prior chemotherapy in the metastatic setting; or
Patient must have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; AND
Patient must have received or be ineligible for endocrine therapy in the metastatic setting, if hormone receptor positive; AND
Patient must have, at the time of initiating treatment with this drug, a WHO performance status no higher than 1; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND
The treatment must not be prescribed where any of the following is present: (i) left ventricular ejection fraction of less than 50%, (ii) symptomatic heart failure; confirm cardiac function testing for the first PBS prescription only; AND
Patient must be undergoing initial treatment with this drug - the following are true: (i) this is the first prescription for this drug, (ii) this prescription seeks no more than 3 repeat prescriptions; or
Patient must be undergoing continuing treatment with drug - the following are true: (i) there has been an absence of further disease progression whilst on active treatment with this drug, (ii) this prescription does not seek to re-treat after disease progression, (iii) this prescription seeks no more than 8 repeat prescriptions.
HER2-low is defined as an immunohistochemical (IHC) score of 1+ or an IHC score of 2+ and a negative result on in situ hybridization (ISH).
Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription:
1) Evidence of HER2-low status
2) Details of prior drug regimens prescribed for the patient
3) Cardiac function test results
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2
Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg.
Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.